Mr. Pennachio called for federal and state governments to use HCQ to tackle the spread of COVID-19, the illness caused by the novel coronavirus, in response to a peer-reviewed study by French infectious disease specialist Didier Raoult, MD, PhD.
In the study, Dr. Raoult demonstrated positive results for the treatment of COVID-19 with HCQ, which has the ability to prevent the virus from entering the cell as well as reproducing.
Dr. Raoult found a substantial decrease in “viral shedding” from patients treated with HCQ, which reduces the likelihood of the virus being transmitted to others.
HCQ also has a 22-day half-life within the body, reinforcing its efficacy for the treatment of COVID-19.
More articles on practice management:
NuVasive recalls Magec system for scoliosis, advises surgeons to perform clinical follow-ups
Zimmer Biomet asks European hospitals to remove orthopedic spacer molds
Resurgens Orthopaedics postpones elective surgeries, remains open for urgent care
